Literature DB >> 9821299

Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27.

F Asanuma1, Y Yamada, E Kawamura, K Lee, H Kobayashi, T Yamada, T Suzuki, T Kubota.   

Abstract

The antitumor effect of paclitaxel, epirubicin, and both in combination was tested using R-27, an estrogen receptor-positive human breast carcinoma. In an in vivo study using nude mice both drugs showed an additive effect, whereas they showed a supraadditive pattern in in vitro MTT assay. The combination of paclitaxel and epirubicin may enhance the antitumor effect on breast carcinoma.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9821299     DOI： 10.1007/bf02820793

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN： 0015-5632            Impact factor:   2.099


  6 in total

1.  Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro.

Authors:  M Akutsu; Y Kano; S Tsunoda; K Suzuki; Y Yazawa; Y Miura
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

2.  Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice.

Authors:  T Kubota; S W Matsuzaki; Y Hoshiya; M Watanabe; M Kitajima; F Asanuma; Y Yamada; J I Koh
Journal:  J Surg Oncol       Date:  1997-02       Impact factor: 3.454

3.  Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.

Authors:  H J Luck; C Thomssen; A duBois; B W Lisboa; M Untch; H Kuhnle; G Konecny; F Janicke; H G Meerpohl; C Lindner; D Hecker; K Diergarten
Journal:  Semin Oncol       Date:  1996-02       Impact factor: 4.929

4.  Preoperative taxol induces objective responses in primary breast cancer not responding to FEC treatment.

Authors:  G G Steger; M P Djavanmard; M F Gnant; R Jakesz
Journal:  Ann Oncol       Date:  1994-11       Impact factor: 32.976

5.  Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells.

Authors:  H Nawata; D Bronzert; M E Lippman
Journal:  J Biol Chem       Date:  1981-05-25       Impact factor: 5.157

6.  Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.

Authors:  S M Hahn; J E Liebmann; J Cook; J Fisher; B Goldspiel; D Venzon; J B Mitchell; D Kaufman
Journal:  Cancer       Date:  1993-11-01       Impact factor: 6.860
  6 in total
  1 in total

Review 1.  Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.

Authors:  D Ormrod; K Holm; K Goa; C Spencer
Journal:  Drugs Aging       Date:  1999-11       Impact factor: 3.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.